Do analysts recommend FLNA or GRTX?

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 281.68%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cassava Sciences is more favorable than Galera Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, FLNA or GRTX?

Cassava Sciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Galera Therapeutics N/A N/A -$59.08M $0.64 0.14

Is FLNA or GRTX more profitable?

Galera Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Galera Therapeutics N/A N/A -99.34%

Do analysts rate GRTX or IMMP?

Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,128.50%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Galera Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, GRTX or IMMP?

Prima BioMed has higher revenue and earnings than Galera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galera Therapeutics N/A N/A -$59.08M $0.64 0.14 Prima BioMed $6.69M 9.86 -$39.78M N/A N/A

Is GRTX or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Prima BioMed N/A N/A N/A

Do analysts rate BHST or GRTX?

BioHarvest Sciences presently has a consensus target price of $10.00, indicating a potential upside of 244.83%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe BioHarvest Sciences is more favorable than Galera Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend GRTX or TLPH?

Talphera has a consensus price target of $3.00, suggesting a potential upside of 152.10%. Given Talphera's stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Galera Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is GRTX or TLPH more profitable?

Galera Therapeutics' return on equity of 0.00% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Talphera N/A -92.98% -53.22%

Do analysts prefer GRTX or TCRX?

TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 460.75%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Galera Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TScan Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Galera Therapeutics (GRTX) Competitors

$0.09 +0.00 (+1.02%)

As of 02:40 PM Eastern

Compare

GRTX vs. FLNA, IMMP, BHST, TLPH, and TCRX

Should you buy Galera Therapeutics stock or one of its competitors? MarketBeat compares Galera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galera Therapeutics include Cassava Sciences (FLNA), Prima BioMed (IMMP), BioHarvest Sciences (BHST), Talphera (TLPH), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.

How does Galera Therapeutics compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Neutral
Galera Therapeutics	Neutral

Cassava Sciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

Cassava Sciences has a beta of -0.73, meaning that its stock price is 173% less volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.6, meaning that its stock price is 160% more volatile than the broader market.

Galera Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Galera Therapeutics	N/A	N/A	-99.34%

Cassava Sciences currently has a consensus price target of $5.00, suggesting a potential upside of 281.68%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cassava Sciences is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Galera Therapeutics beats Cassava Sciences on 7 of the 11 factors compared between the two stocks.

How does Galera Therapeutics compare to Prima BioMed?

Galera Therapeutics (NASDAQ:GRTX) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Galera Therapeutics has a beta of 2.6, indicating that its share price is 160% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,128.50%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Prima BioMed	N/A	N/A	N/A

Prima BioMed has higher revenue and earnings than Galera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
Prima BioMed	$6.69M	9.86	-$39.78M	N/A	N/A

In the previous week, Prima BioMed had 5 more articles in the media than Galera Therapeutics. MarketBeat recorded 5 mentions for Prima BioMed and 0 mentions for Galera Therapeutics. Galera Therapeutics' average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Prima BioMed	Neutral

Summary

Prima BioMed beats Galera Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Galera Therapeutics compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

BioHarvest Sciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.6, indicating that its stock price is 160% more volatile than the broader market.

Galera Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Galera Therapeutics' return on equity of 0.00% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Galera Therapeutics	N/A	N/A	-99.34%

BioHarvest Sciences has higher revenue and earnings than Galera Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.16M	1.62	-$11.14M	-$0.59	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

In the previous week, BioHarvest Sciences' average media sentiment score of 0.00 equaled Galera Therapeutics'average media sentiment score.

Company	Overall Sentiment
BioHarvest Sciences	Neutral
Galera Therapeutics	Neutral

BioHarvest Sciences presently has a consensus target price of $10.00, indicating a potential upside of 244.83%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe BioHarvest Sciences is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

50.8% of Galera Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Galera Therapeutics beats BioHarvest Sciences on 7 of the 13 factors compared between the two stocks.

How does Galera Therapeutics compare to Talphera?

Galera Therapeutics (NASDAQ:GRTX) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 3.5% of Talphera shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Talphera had 1 more articles in the media than Galera Therapeutics. MarketBeat recorded 1 mentions for Talphera and 0 mentions for Galera Therapeutics. Galera Therapeutics' average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Talphera	Neutral

Galera Therapeutics has a beta of 2.6, suggesting that its stock price is 160% more volatile than the broader market. Comparatively, Talphera has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Talphera has higher revenue and earnings than Galera Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
Talphera	$30K	2,058.70	-$14.29M	-$0.31	N/A

Talphera has a consensus price target of $3.00, suggesting a potential upside of 152.10%. Given Talphera's stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Galera Therapeutics' return on equity of 0.00% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Talphera	N/A	-92.98%	-53.22%

Summary

Talphera beats Galera Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Galera Therapeutics compare to TScan Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Galera Therapeutics has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,360.61%. Galera Therapeutics' return on equity of 0.00% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
TScan Therapeutics	-1,360.61%	-91.94%	-50.15%

TScan Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 460.75%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TScan Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Galera Therapeutics has a beta of 2.6, indicating that its share price is 160% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled TScan Therapeutics'average media sentiment score.

Company	Overall Sentiment
Galera Therapeutics	Neutral
TScan Therapeutics	Neutral

Galera Therapeutics has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
TScan Therapeutics	$10.32M	6.78	-$129.77M	-$0.96	N/A

Summary

Galera Therapeutics beats TScan Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRTX vs. The Competition

Export

Metric	Galera Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.28M	$966.05M	$6.95B	$12.44B
Dividend Yield	N/A	4.84%	2.67%	6.52%
P/E Ratio	-0.25	1.61	27.22	24.45
Price / Sales	N/A	115.50	532.40	95.17
Price / Cash	N/A	22.05	29.65	49.26
Price / Book	-0.04	8.38	10.97	6.42
Net Income	-$59.08M	-$3.96M	$3.56B	$335.85M
7 Day Performance	N/A	-0.96%	1.76%	-0.48%
1 Month Performance	N/A	3.35%	6.66%	3.38%
1 Year Performance	N/A	48.20%	36.05%	24.97%

Galera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRTX Galera Therapeutics	N/A	$0.09 +1.0%	N/A	+199.7%	$14.28M	N/A	N/A	30
FLNA Cassava Sciences	1.5795 of 5 stars	$1.17 -1.3%	$5.00 +329.2%	-37.8%	$56.28M	N/A	N/A	20	Positive News
IMMP Prima BioMed	1.4298 of 5 stars	$0.38 -2.0%	$5.50 +1,347.4%	-74.1%	$56.00M	$6.69M	N/A	2,021	Gap Down
BHST BioHarvest Sciences	3.1409 of 5 stars	$2.84 -2.6%	$10.00 +252.7%	-58.1%	$55.62M	$34.51M	N/A	N/A	Positive News Gap Up
TLPH Talphera	2.4679 of 5 stars	$1.07 +0.8%	$3.00 +180.6%	+153.8%	$55.48M	$1K	N/A	19

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRTX) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galera Therapeutics (GRTX) Competitors

GRTX vs. FLNA, IMMP, BHST, TLPH, and TCRX

How does Galera Therapeutics compare to Cassava Sciences?

Summary

How does Galera Therapeutics compare to Prima BioMed?

Summary

How does Galera Therapeutics compare to BioHarvest Sciences?

Summary

How does Galera Therapeutics compare to Talphera?

Summary

How does Galera Therapeutics compare to TScan Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTX vs. The Competition

Galera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galera Therapeutics (GRTX) Competitors

GRTX vs. FLNA, IMMP, BHST, TLPH, and TCRX

How does Galera Therapeutics compare to Cassava Sciences?

Does the media prefer FLNA or GRTX?

Which has better earnings & valuation, FLNA or GRTX?

Which has more volatility and risk, FLNA or GRTX?

Is FLNA or GRTX more profitable?

Do analysts recommend FLNA or GRTX?

Do insiders & institutionals hold more shares of FLNA or GRTX?

Summary

How does Galera Therapeutics compare to Prima BioMed?

Which has more volatility and risk, GRTX or IMMP?

Do insiders and institutionals believe in GRTX or IMMP?

Do analysts rate GRTX or IMMP?

Is GRTX or IMMP more profitable?

Which has higher earnings and valuation, GRTX or IMMP?

Does the media prefer GRTX or IMMP?

Summary

How does Galera Therapeutics compare to BioHarvest Sciences?

Which has more volatility & risk, BHST or GRTX?

Is BHST or GRTX more profitable?

Which has preferable valuation and earnings, BHST or GRTX?

Does the media prefer BHST or GRTX?

Do analysts rate BHST or GRTX?

Do insiders & institutionals believe in BHST or GRTX?

Summary

How does Galera Therapeutics compare to Talphera?

Do institutionals and insiders have more ownership in GRTX or TLPH?

Does the media prefer GRTX or TLPH?

Which has more risk & volatility, GRTX or TLPH?

Which has preferable valuation and earnings, GRTX or TLPH?

Do analysts recommend GRTX or TLPH?

Is GRTX or TLPH more profitable?

Summary

How does Galera Therapeutics compare to TScan Therapeutics?

Is GRTX or TCRX more profitable?

Do analysts prefer GRTX or TCRX?

Which has more volatility and risk, GRTX or TCRX?

Do institutionals and insiders hold more shares of GRTX or TCRX?

Does the media refer more to GRTX or TCRX?

Which has stronger valuation and earnings, GRTX or TCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRTX vs. The Competition

Galera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools